Роль кишкової мікробіоти в патофізіології спондилоартритів. Досягнення в терапевтичній корекції мікробіому
DOI:
https://doi.org/10.30978/MG-2018-6-62Ключові слова:
мікробіом, анкілозувальний спондиліт, спондилоартрит, HLA-B27, патогенез, трансплантація фекальної мікробіотиАнотація
Розширюється уявлення про механізми впливу мікробіоти за межами її первинної локалізації (слизова оболонка кишечника) на інші органи і системи. Бактерії, наявні в кишечнику, значно впливають на імунну систему носія як на місцевому, так і на віддаленому рівні. Як відомо, мікробіом кишечника відіграє певну роль у патогенезі запальних захворювань кишечника. Є багато спільних клінічних виявів запальних захворювань кишечника і спондилоартриту. Клінічний оверлап разом з подібною генетикою між цими захворюваннями передбачає можливий спільний патогенетичний механізм, який, імовірно, зумовлений станом мікробіоти кишечника. Розглянуто докази ролі мікробіому в етіології та патогенезі спондилоартриту. Висвітлено парадигми лікування, спрямовані на зміну мікробіоти кишечника при спондилоартриті.
Посилання
Abreu MT, Fukata M, Breglio K. Innate immunity and its implications on pathogenesis of inflammatory bowel disease / Ed. by S. R. Targan, F. Shanahan, L. C. Karp. Inflammatory bowel disease. Oxford: Blackwell Publishing Ltd., 2010. P. 64-81.
Amdekar S, Singh V, Singh R et al. Lactobacillus casei reduces the inflammatory joint damage associated with collagen-induced arthritis (CIA) by reducing the pro-inflammatory cytokines: Lactobacillus casei: COX-2 inhibitor. J Clin Immunol. 2011;Vol. 31, N2. P. 147-154. DOI:10.1007/s10875-010-9457-7.
Arumugam M, Raes J, Pelletier E et al. Enterotypes of the human gut microbiome. Nature. 2011;Vol. 473. P. 174-180. DOI:10.1038/nature09944
Asquith M, Davin S, Stauffer P et al. Intestinal metabolites are profoundly alteredin the context of HLA-B27 expression and functionally modulate disease in a rat model of spondyloarthritis. Arthritis Rheumatol. 2017;Vol. 69. P. 1984-1995. doi: 10.1002/art.40183.
Bafeta A, Yavchitz A, Riveros C et al. Methods and reporting studies assessing fecal microbiota transplantation: a systematic review. Ann Intern Med —2017. Vol. 167. P. 34-39. doi: 10.7326/M16-2810.
Bisanz JE, Suppiah P, Thomson WM et al. The oral microbiome of patients with axial spondyloarthritis compared to healthy individuals. Peer J. 2016;Vol. 4. P. 2095. doi: [10.3390/ijms17122126].
Borody TJ, Warren EF, Leis SM et al. Bacierioiherapy using fecal flora: toying with human motions. J Clin Gastroenterol —2004. Vol. 38, N 6. P. 475-483.
Breban M, Tap J, Leboime A et al. Faecal microbiota study reveals specific dysbiosis in spondyloarthritis. Ann Rheum Dis. 2017;Vol. 76. P. 1614-1622. doi: 10.1136/annrheumdis-2016-21106.
Buckley CD, Gilroy DW, Serhan CN et al. The resolution of inflammation. Nat Rev Immunol. 2013;Vol. 13 (1). P. 59-66. doi: 10.1038/nri3362.
Castagnini C, Luceri C, Toti S et al. Reduction of colonic inflammation in HLA- B27 transgenic rats by feeding Marie Menard apples, rich in polyphenols. Br J Nutr —2009. Vol. 102. P. 1620-1628. doi: 10.1017/S0007114509990936.
Ciccia F, Guggino G, Rizzo A et al. Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis. Ann Rheum Dis. 2015;Vol. 74, N 9. P. 1739-47. doi: 10.1136/annrheumdis-2014-206323.
Costello ME, Ciccia F, Willner D et al. Intestinal dysbiosis in ankylosing spondylitis. Arthritis Rheum. 2015;Vol. 67, N 3. P. 686-691. doi: 10.1002/art.38967.
Costello ME, Robinson PC, Benham H, Brown MA. The intestinal microbiome in human disease and how it relates to arthritis and spondyloarthritis. Best Pract Res Clin Rheumatol. 2015;Vol. 29, N 2. P. 202-212.
De Vos M, Mielants H, Cuvelier C et al. Long-term evolution of gut inflammation in patients with spondyloarthropathy. Gastroenterol. 1996;Vol. 110. P. 1696-1703.
Dong M, Yu D, Duraipandiyan V, Abdullah Al-Dhabi N. Corrigendum «The protective effect of Chrysanthemum indicum extract against ankylosing spondylitis in mouse models». Biomed Res Int. 2017;Vol. 2017. P. 8206281. doi: [10.1155/2018/8097342].
Eckburg PB, Bik EM, Bernstein CN et al. Diversity of the human intestinal microbial flora. Science. 2005;Vol. 308. P. 1635-1638. DOI:10.1126/science.1110591.
Eiseman B, Silen W, Bascom GS, Kauvar AJ. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery. 1958;Vol. 44. P. 854-859.
Erickson AR, Cantarel BL, Lamendella R et al. Integrated metagenomics / metaproteomics reveals human host-microbiota signatures of Crohn’s disease. PLoS One. 2012;Vol. 7, N 11. P. 49138. doi: 10.1371/journal.pone.0049138.
Gao Z, Tseng CH, Strober BE et al. Substantial alterations of the cutaneous bacterial biota in psoriatic lesions. PLoS One. 2008;Vol. 3, N 7. P. 2719. DOI:10.1371/journal.pone.0002719.
Goel R, Danda D, Avinash B et al. Clinico-pathological correlation of non specific inflammation in bowel histology with joint manifestation in a tertiary center in South India. Rheumatol Int. 2013;Vol. 33. P. 2149-2152. DOI:10.1016/j.cgh.2013.02.030.
Goldblatt F, O’Neill SG. Clinical aspects of autoimmune rheumatic diseases. Lancet —2013. Vol. 382. P. 797-808. doi: 10. 1016/S0140-6736 (13)61499-3.
Hoentjen F, Welling GW, Harmsen HJ et al. Reduction of colitis by prebiotics in HLA-B27 transgenic rats is associated with microflora changes and immunomodulation. Inflam Bowel Dis —2005. Vol. 11. P. 977-985.
Huttenhower C, Kostic AD, Xavier RJ. Inflammatory bowel disease as a model for translating the microbiome. Immunity. 2014;Vol. 40. P. 843-854. doi: 10.1016/j.immuni.2014.05.013.
Jacques P, van Praet L, Carron P et al. Pathophysiology and role of the gastrointestinal system in spondyloarthritides. Rheum Dis Clin North Am. 2012;Vol. 38, N 3. P. 569-582.
Jenks K, Stebbings S, Burton J et al. Probiotic therapy for the treatment of spondyloarthritis: a randomized controlled trial. J Rheumatol. 2010;Vol. 37. P. 2118-2125. doi: 10.3899/jrheum.100193.
Jostins L, Ripke S, Weersma RK et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;Vol. 491, N 7422. P. 119-124. doi: 10.1038/nature11582.
Klingberg E, Carlsten H, Hilme E et al. Calprotectin in ankylosing spondylitis: frequently elevated in feces, but normal in serum. Scand J Gastroenterol —2012. Vol. 47. P. 435-444. doi: 10.3109/00365521.2011.648953.
Knights D, Ward TL, McKinlay CE et al. Rethinking «enterotypes». Cell Host Microbe. 2014;Vol. 16, N 4. P. 433-437. doi: 10.1016/j.chom.2014.09.013.
Koren O, Knights D, Gonzalez A et al. A guide to enterotypes across the human body: meta-analysis of microbial community structures in human microbiome datasets. PLoS Comput Biol. 2013;Vol. 9, N 1. P.e1002863. doi: 10.1371/journal.pcbi.1002863.
Kriegel MA. Self or non-self? The multifaceted role of the microbiota in immune-mediated diseases. Clin Immunol. 2015;Vol. 159, N 2. P. 119-121. doi: 10.1016/j.clim.2015.05.010.
Kuhn KA, Pedraza I, Demoruelle K. Mucosal immune responses to microbiota in the development of autoimmune disease. Rheum Dis Clin N Am. 2014;Vol. 40. P. 711-725. doi: 10.1016/j.rdc.2014.07.013.
Kuon W, Holzhutter HG, Appel H et al. Identification of HLA-B27-restricted peptides from the Chlamydia trachomatis proteome with possible relevance to HLA-B27-associated diseases. J Immunol. 2001;Vol. 167, N 8. P. 4738-4746. doi: [10.1074/jbc.M113.493247.
Landers CJ, Cohavy O, Misra R et al. Selected loss of tolerance evidenced by Crohn’s disease-associated immune responses to auto- and microbial antigens. Gastroenterology. 2002;Vol. 123, N 3. P. 689-699.
Lopez J, Grinspan A. Fecal Microbiota Transplantation for Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2016;Vol. 12, N 6. P. 374-379.
May E, Marker-Hermann E, Wittig BM et al. Identical T-cell expansions in the colon mucosa and the synovium of a patient with enterogenic spondyloarthropathy. Gastroenterology. 2000;Vol. 119, N 6. P. 1745-1755. doi:10.1053/gast.2000.20173.
Mielants H, Veys EM, Cuvelier C et al. The evolution of spondyloarthropathies in relation to gut histology. II. Histological aspects. J Rheumatol. 1995;Vol. 22. P. 2273-2278.
Moghimi J, Rezaei AA, Ghorbani R et al. Efficacy of an acquainted drug in the treatment of inflammatory low back pain: sulfasalazine under investigation. Drug Des Devel Ther. 2016;Vol. 10. P. 3065-3069. DOI:10.2147/DDDT.S111568.
Morton AM, Sefik E, Upadhyay R et al. Endoscopic photoconversion reveals unexpectedly broad leukocyte trafficking to and from the gut. Proc Natl Acad Sci USA. 2014;Vol. 111, N 18. P. 6696-6701. doi: 10.1073/pnas.1405634111.
Nakamura YK, Janowitz C, Metea C et al. Short chain fatty acids ameliorate && immune-mediated uveitis partially by altering migration of lymphocytes from the intestine. Sci Rep –2017. Vol. 7. P. 11745. http://doi.org/10.1038/s41598-017-12163-3.
Noto Llana M, Sarnacki SH, Aya Castaneda MR et al. Consumption of lactobacillus casei fermented milk prevents Salmonella reactive arthritis by modulating IL-23/IL-17 expression. PLoS One. 2013;Vol. 8, N 12. P. 82588. doi: 10.1371/journal.pone.0082588.
Ogrendik M. Treatment of ankylosing spondylitis with moxifloxacin. South Med J. 2007;Vol. 100. P. 366-370. DOI:10.1097/SMJ.0b013e31802fa2a8.
Pineda ML, Thompson SF, Summers K et al. A randomized, double-blinded, placebo- controlled pilot study of probiotics in active rheumatoid arthritis. Med Sci Monit. 2011;Vol. 17, N 6. P. 347-354.
Poddubnyy D, Rudwaleit M. Early spondyloarthritis. Rheum Dis Clin N Am. 2012;Vol. 38, N 2. P. 387. doi: 10.1016/j.rdc.2012.04.007.
Prindiville T, Cantrell M, Wilson KH. Ribosomal DNA sequence analysis of mucosa-associated bacteria in Crohn’s disease. Inflam Bowel Dis —2004. Vol. 10. P. 824-833. http://doi.org/10.1097/00054725-200411000-00017.
Puccetti A, Dolcino M, Tinazzi E et al. Antibodies directed against a peptide epitope of a Klebsiella pneumoniae-derived protein are present in ankylosing spondylitis. PLoS One. 2017;Vol. 12. P. 0171073. doi: [10.1371/journal.pone.0171073].
Qin J, Li R, Raes J et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;Vol. 464. P. 59-65. doi: 10.1038/nature08821.
Rashid T, Ebringer A. Ankylosing spondylitis is linked to Klebsiella the evidence. Clin Rheumatol. 2007;Vol. 26, N 6. P. 858-864. DOI:10.1007/s10067-006-0488-7.
Raza K, Gerlag DM. Preclinical inflammatory rheumatic diseases. Rheum Dis Clin North Am. 2014;Vol. 40, N 4. P. 569-580. doi: 10.1016/j.rdc.2014.07.001.
Ruff WE, Kriegel MA. Autoimmune host-microbiota interactions at barrier sites and beyond. Trends Mol Med. 2015;Vol. 21, N 4. P. 233-244. doi: 10.1016/j.molmed.2015.02.006.
Ruutu M, Thomas G, Steck R et al. Beta-glucan triggers spondylarthritis and Crohn’s disease-like ileitis in SKG mice. Arthritis Rheum. 2012;Vol. 64. P. 2211-2222. doi: 10.1002/art.34423.
Salmi M, Jalkanen S. Human leukocyte subpopulations from inflamed gut bind to joint vasculature using distinct sets of adhesion molecules. J Immunol. 2001;Vol. 166, N 7. P. 4650-4657.
Sanges M, Valente G, Rea M et al. Probiotics in spondyloarthropathy associated with ulcerative colitis: a pilot study. Eur Rev Med Pharmacol Sci. 2009;Vol. 13. P. 233-234.
Scarpa R, Manguso F, D’Arienzo A et al. Microscopic inflammatory changes in colon of patients with both active psoriasis and psoriatic arthritis without bowel symptoms. J Rheumatol. 2000;Vol. 27. P. 1241-1246.
Schaeverbeke T, Truchetet ME, Richez C. Gut metagenome and spondyloarthritis. Joint Bone Spine. 2013;Vol. 80, N 4. P. 349-352. doi: 10.1016/j.jbspin.2013.02.005.
Scher JU, Ubeda C, Artacho A et al. Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease. Arthritis Rheum. 2015;Vol. 67, N 1. P. 128-139. doi: 10.1002/art.38892.
Sekirov I, Russell SL, Atunes LC, Finlay BB. Gut microbiota in health and disease. Physiol Rev —2010. Vol. 90. P. 859-904. doi: 10.1152/physrev.00045.2009.
Sharma SK, Kadiyala V, Naidu G, Dhir V. A randomized controlled trial to study the efficacy of sulfasalazine for axial disease in ankylosing spondylitis. Int J Rheum Dis. 2017;Vol. 21. P. 308-314. doi: 10.1111/1756-185X.13124.
Shivashankar R, Loftus EV, Tremaine WJ et al. Incidence of Spondyloarthropathy in patients with ulcerative colitis: a population-based study. J Rheumatol. 2013;Vol. 40. P. 1153-1157. doi: [10.3899/jrheum.121029].
Shukla A, Gaur P, Aggarwal A. Double blind placebo controlled randomized trial of probiotics in Enthesitis-related-arthritis category of JIA: effect on clinical and immunological parameters. Arthritis Rheum. 2015;Vol. 67. P. 10. doi: 10.1002/cncr.23328.
Sommer F, Backhed F. The gut microbiota — masters of host development and physiologу. Nat Rev Microbiol. 2013;Vol. 11, N 4. Р. 227-223. doi: 10.1038/nrmicro2974.
Stoll ML, Kumar R, Morrow CD et al. Altered microbiota associated with abnormal humoral immune responses to commensal organisms in enthesitis- related arthritis. Arthritis Res Ther. 2014;Vol. 16, N 6. P. 486. doi: 10.1186/s13075-014-0486-0.
Stoll ML. Gut microbes, immunity, and spondyloarthritis. Clin Immunol. 2015;Vol. 159, N 2. P. 134-142. doi: 10.1016/j.clim.2015.05.001.
Telfer NR, Chalmers RJ, Whale K, Colman G. The role of streptococcal infection in the initiation of guttate psoriasis. Arch Dermatol. 1992;Vol. 128. P. 39-42.
Tito RY, Cypers H, Joossens M et al. Dialister as microbial marker of disease activity in spondyloarthritis. Arthritis Rheumatol. 2016;Vol. 69, N 1. P. 114-121. doi: 10.1002/art.39802.
Tursi A, Brandimarte G, Papa A et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double- blind, randomized, placebo-controlled study. Am J Gastroenterol —2010. Vol. 105, N 10. P. 2218-2227. doi: 10.1038/ajg.2010.218.
Van der Horst-Bruinsma IE, Nurmohamed MT, Landewe RB. Comorbidities in patients with spondyloarthritis. Rheum Dis Clin North Am. 2012;Vol. 38. P. 523-538. doi: 10.1016/j.rdc.2012.08.010.
Van Praet L, Van den Bosch FE, Jacques P et al. Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model. Ann Rheum Dis. 2013;Vol. 72. P. 414-417. doi: 10.1136/annrheumdis-2012-202135.
Van Praet L, Jans L, Carron P et al. Degree of bone marrow edema in sacroiliac joints of patients with axial spondyloarthritis is linked to gut inflammation and male sex: results from the GIANT cohort. Ann Rheum Dis. 2014;Vol. 73, N 6. P. 1186-1189. doi: 10.1136/annrheumdis-2013-203854.
Vlam K. de, Mielants H, Cuvelier C et al. Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. J Rheumatol. 2000;Vol. 27. P. 2860-2865.
Walker AW. Dominant and diet-responsive groups of bacteria within the human colonic microbiota. ISME J. 2011;N 5. Р. 220-230. doi: 10.1038/ismej.2010.118.
Wang ZK, Yang YS, Chen Y et al. Intestinal microbiota pathogenesis and fecal microbiota transplantation for inflammatory bowel disease. World J Gastroenterol. 2014;Vol. 20, N 40. P. 14805-14820. doi: [10.3748/wjg.v20.i40.14805].
Zhang F, Luo W, Shi Y et al. Should we standardize the 1700-year old fecal microbiota transplantation?. Am J Gastroenterol —2012. Vol. 107, N 11. P. 1755. doi: 10.1038/ajg.2012.251.
